New Version of Hepatitis C Drug More Effective
Doctors are hopeful a new version of a drug could help hepatitis C sufferers. Two studies, sponsored by the drug maker Hoffmann-La Roche Inc, tested a modified form of interferon called Pegasys against the standard Roferon-A.
The findings show that Pegasys is more effective and has fewer side effects.
There are four million Americans infected with hepatitis C, which can cause liver inflammation, cirrhosis, and cancer. The standard treatment for the disease has been injections of interferon alpha or a combination of interferon and another antiviral drug ribavirin.
Hoffmann-La Roche has applied for Food and Drug Administration approval to sell Pegasys. Schering-Plough Corp. is also looking for approval on a similarly modified interferon, Peg-Intron. Studies using Peg-Intron show it to be effective in 54% of patients.
Information from www.usatoday.com.
I Was There: An Infection Preventionist on the COVID-19 Pandemic
April 30th 2025Deep feelings run strong about the COVID-19 pandemic, and some beautiful art has come out of those emotions. Infection Control Today is proud to share this poem by Carmen Duke, MPH, CIC, in response to a recent article by Heather Stoltzfus, MPH, RN, CIC.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
